Request Appointment
530 East 74th StreetNew York, NY 10021
Overview of Dr. Yu
Dr. Helena Yu is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from University of Michigan Medical School and has been in practice 10 years. She is one of 505 doctors at Memorial Sloan Kettering Cancer Center and one of 86 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
University of Michigan Medical SchoolClass of 2007
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2027
NY State Medical License 2010 - 2027
PA State Medical License 2007 - 2010
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer Start of enrollment: 2004 Aug 01
- Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Start of enrollment: 2013 Oct 15
- Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherap...Zofia Piotrowska, Antonio Passaro, Danny Nguyen, Gerrina Ruiter, Ross A Soo
Journal of Clinical Oncology. 2025-07-20 - Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection.Gabriele Campanella, Neeraj Kumar, Swaraj Nanda, Siddharth Singi, Eugene Fluder
Nature Medicine. 2025-07-09 - ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth F...Jonathan W Riess, Adrianus J de Langen, Santiago Ponce, Sarah B Goldberg, Zofia Piotrowska
JCO Precision Oncology. 2025-06-01
Journal Articles
- Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung CancersHelena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAlexander I Spira, Helena A Yu, Clinical Lung Cancer
- YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical GenomicsEmmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences
Lectures
- A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.2019 ASCO Annual Meeting - 6/1/2019
- Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018
Press Mentions
MSK Researchers Present Advances in Lung Cancer Treatment at 2025 ASCO MeetingJune 2nd, 2025- ASCO: Cullinan, Taiho Unveil Lung Cancer Data Behind FDA Application PlansMay 22nd, 2025
- New Targeted Therapy Strategies for Addressing Non-Small Cell Lung Cancer Metastatic DiseaseMarch 24th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
